NUDT5 and cancer: After validation and formulation, successful candidates will then progress to in vivo studies to evaluate their anti-cancer effects and ultimately into clinical trials to confirm or reject the potential for developing a new generation of drugs for BRCA treatment—NUDT5 inhibitors.